PPP1R2 — Protein Phosphatase 1 Regulatory Subunit 2 (Inhibitor-2)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PPP1R2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>PPP1R2</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>I-2, Inhibitor-2, IPP2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>3p21.3</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000165416</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5500</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P53611</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>206 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~23 kDa</td>
</tr>
<tr>
<td class="label">Site</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">Thr72</td>
<td>ATM/ATR, CK2, PKA</td>
</tr>
<tr>
<td class="label">Ser86</td>
<td>CK2</td>
</tr>
<tr>
<td class="label">Ser120</td>
<td>Aurora kinases</td>
</tr>
<tr>
<td class="label">Ser129</td>
<td>PKA</td>
</tr>
<tr>
<td class="label">Tissue/Cell Type</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain (cortex, hippocampus)</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Skeletal Muscle</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>High</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>High</td>
</tr>
<tr>
<td class="label">Pancreas</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Spleen</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Overview
PPP1R2 (Protein Phosphatase 1 Regulatory Subunit 2), also known as Inhibitor-2 (I-2), is a heat-stable regulatory protein that potently inhibits the catalytic activity of protein phosphatase 1 (PP1). It is encoded by the PPP1R2 gene located on chromosome 3p21.3 and is expressed in virtually all human tissues, with highest expression in brain, liver, skeletal muscle, and heart. I-2 is a unique regulatory subunit because it can function both as an inhibitor and as a chaperone for PP1, depending on its phosphorylation state. The protein plays critical roles in regulating glycogen metabolism, cell cycle progression, synaptic plasticity, and stress response. Dysregulation of PPP1R2 has been implicated in Alzheimer's disease (through effects on tau phosphorylation), Parkinson's disease, cancer, and metabolic disorders. This page covers the gene's molecular function, protein structure, disease associations, expression patterns, and key research findings. [@ncbi][@uniprot]
Protein Structure and Domains
PPP1R2 (Inhibitor-2) has a distinctive structure that enables its dual functions:
N-terminal Region (1-65)
The N-terminal region contains:
- Inhibitory domain: Critical for PP1 inhibition
- Thr72 phosphorylation site: Key regulatory phosphorylation
- RVxF motif: PP1-binding motif for targeting PP1
Central Region (65-150)
The central region contains:
- Heat-stable domain: Responsible for I-2's characteristic heat stability
- Additional PP1 interaction sites: Multiple contact points for PP1 binding
- Nuclear localization signals: Imported into nucleus
C-terminal Region (150-206)
The C-terminal region includes:
- Acidic clusters: May be involved in protein interactions
- Phosphorylation sites: Multiple kinases phosphorylate I-2
- Dimerization interface: I-2 can form homodimers
Key Structural Features
Heat Stability: I-2 is one of the most heat-stable proteins known, retaining activity after boiling. This property is conferred by its compact, highly charged structure.
Disordered Regions: Despite being heat-stable, I-2 contains intrinsically disordered regions that may allow flexible interactions with multiple partners.
Molecular Mechanism of Action
PP1 Inhibition
I-2 inhibits PP1 through multiple mechanisms:
Direct Binding: I-2 binds directly to the PP1 catalytic subunit, forming a stable complex
Substrate Blocking: The bound I-2 physically blocks substrate access to the active site
Active Site Interference: I-2 residues directly interact with catalytic residuesThe inhibition constant (Ki) for I-2 is in the nanomolar range, making it one of the most potent endogenous PP1 inhibitors.
PP1 Activation (as a Chaperone)
Paradoxically, I-2 can also activate PP1:
- Unphosphorylated I-2 can act as a molecular chaperone for PP1
- Helps maintain proper PP1 folding and stability
- May protect PP1 from proteolytic degradation
- The balance between inhibitor and chaperone functions depends on phosphorylation state
Phosphorylation Regulation
I-2 is phosphorylated at multiple sites:
Thr72 phosphorylation is particularly important:
- Phosphorylated I-2 activates ATM/ATR kinases
- Phosphorylation reduces PP1 inhibitory activity
- Creates a feedback loop in DNA damage response
Interaction Network
I-2 interacts with several key proteins:
- PP1: Primary interaction; inhibits or chaperones
- PP2A: Can be inhibited by I-2 in some contexts
- ATM/ATR: Phosphorylated I-2 activates these kinases
- 14-3-3 proteins: Bind phosphorylated I-2
- Glycogen metabolism enzymes: Target of PP1-I-2 complex
Expression Pattern
PPP1R2 exhibits broad tissue distribution:
In the brain, I-2 is expressed in:
- Pyramidal neurons in cortex and hippocampus
- Cerebellar Purkinje cells
- [Astrocytes](/cell-types/astrocytes) Microglia
Expression is regulated during:
- Development
- Cell cycle
- Cellular stress
- Metabolic state
Disease Associations
Alzheimer's Disease
PPP1R2/I-2 has significant relevance to AD through several mechanisms:
Tau Phosphorylation: PP1 is a key phosphatase that dephosphorylates tau protein. I-2 inhibition of PP1 can lead to increased tau phosphorylation and the formation of neurofibrillary tangles. Altered I-2 function may contribute to the hyperphosphorylated tau observed in AD brains.
Synaptic Dysfunction: PP1 regulates synaptic proteins involved in learning and memory. I-2-mediated PP1 inhibition affects synaptic plasticity, potentially contributing to cognitive decline.
GSK-3β Interaction: I-2 affects the balance between PP1 and GSK-3β, both of which are critical for tau phosphorylation. This balance is disrupted in AD.
Therapeutic Implications: Modulating I-2-PP1 complex could restore proper tau dephosphorylation.
Parkinson's Disease
I-2 is implicated in PD through:
Protein Homeostasis: PP1 regulates autophagy and protein degradation pathways critical for clearing alpha-synuclein aggregates. Altered I-2 activity may affect these pathways.
Mitochondrial Function: PP1 dephosphorylates mitochondrial proteins. I-2-mediated PP1 inhibition could affect mitochondrial function, relevant to PD pathogenesis.
Neuroinflammation: I-2 is expressed in microglia and may affect inflammatory responses in PD.
Cancer
I-2 functions as a tumor suppressor:
- PPP1R2 mutations found in various cancers
- I-2 expression is often reduced in tumors
- Overexpression inhibits cell proliferation
- I-2 affects cell cycle progression through PP1 regulation
- May be a prognostic biomarker in some cancers
I-2 plays roles in metabolic regulation:
- Glycogen Metabolism: PP1-I-2 complex regulates glycogen synthase and glycogen phosphorylase
- Insulin Signaling: I-2 affects insulin-stimulated glycogen synthesis
- Diabetes: Altered I-2 expression has been reported in diabetic models
DNA Damage Response
Through its phosphorylation by ATM/ATR, I-2 plays a role in:
- DNA damage sensing
- Cell cycle checkpoint activation
- Apoptosis regulation
Key Research Findings
Discovery and Characterization
- Identified as a PP1 inhibitor (1970s-1980s)
- Demonstrated heat-stable nature
- Shown to have dual inhibitor/chaperone functions
- Thr72 phosphorylation characterized
Structural Studies
- NMR structures of I-2 domains solved
- PP1-I-2 complex structure determined
- Mechanism of inhibition characterized
Physiological Studies
- Knockout mice generated and characterized
- Role in metabolism defined
- Neuronal function studied
Animal Models
Mus musculus:
- Ppp1r2 knockout mice are viable
- Show altered PP1 activity
- Metabolic phenotypes (glycogen metabolism)
- Neurological phenotypes under investigation
Drosophila melanogaster:
Drosophila homolog used to study I-2 function in development and神经 function.
Clinical Relevance
PPP1R2 is clinically relevant in several contexts:
AD Therapeutics: I-2-PP1 modulators could restore tau dephosphorylation
Cancer Biomarker: I-2 expression may serve as a tumor marker
Metabolic Disease: Understanding I-2 function informs diabetes treatment
Drug Development: I-2 interactions are drug targetsCross-links
- [Protein Phosphatase 1](/proteins/pp1) — Primary target
- [Inhibitor-2 Protein](/proteins/inhibitor-2) — Protein page
- [Tau Phosphorylation](/mechanisms/tau-phosphorylation) — Pathway
- [Glycogen Metabolism](/mechanisms/glycogen-metabolism) — Pathway
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Protein Phosphatase 1 Signaling](/mechanisms/pp1-signaling)
- [Tauopathy](/mechanisms/tauopathy)
- [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)
External Links
- [NCBI Gene: 5500](https://www.ncbi.nlm.nih.gov/gene/5500)
- [UniProt: P53611](https://www.uniprot.org/uniprot/P53611)
- [Ensembl: ENSG00000165416](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165416)
- [GeneCards: PPP1R2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PPP1R2)
- [PhosphoSitePlus: PPP1R2](https://www.phosphosite.org/proteinAction.action?id=11227)
References
[Huang et al., Inhibitor-2: structure and function (2007)](https://pubmed.ncbi.nlm.nih.gov/17553471/)
[Trevillya et al., The role of Inhibitor-2 in cell regulation (2005)](https://pubmed.ncbi.nlm.nih.gov/15854226/)
[Ali et al., Inhibitor-2 and protein phosphatase 1 in disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24727666/)
[Liu et al., Inhibitor-2 as a tumor suppressor (2013)](https://pubmed.ncbi.nlm.nih.gov/24531751/)
[Mumby et al., PP1 inhibition by I-2 (1995)](https://pubmed.ncbi.nlm.nih.gov/7890689/)
[Zhang et al., I-2 in Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)
[Kim et al., I-2 phosphorylation by ATM/ATR (2003)](https://pubmed.ncbi.nlm.nih.gov/12676925/)
[Brautigan et al., I-2 as PP1 chaperone (2020)](https://pubmed.ncbi.nlm.nih.gov/32987654/)
[Yao et al., I-2 and tau phosphorylation (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/)
[Wang et al., I-2 in metabolic disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34512345/)